611
Participants
Start Date
September 26, 2012
Primary Completion Date
March 25, 2016
Study Completion Date
March 25, 2016
peficitinib
oral
Site HU3302, Budapest
Site HU3448, Budapest
Site HU3462, Budapest
Site BE3387, Brussels
Site BE3314, Brussels
Site BG3303, Sofia
Site BG3217, Plovdiv
Site HU3398, Békéscsaba
Site MX3310, México
Site BG3613, Burgas
Site HU3461, Balatonfüred
Site US345, Duncansville
Site US3304, Wyomissing
Site US291, Wheaton
Site US3327, Chesapeake
Site US3320, Clarksburg
Site US3298, Hickory
Site US1894, Jacksonville
Site US3232, Orlando
Site US3218, Birmingham
Site US3306, Knoxville
Site US3329, Elizabethtown
Site MX3307, Guadalajara, Jalisco
Site MX3238, Guadalajara
Site MX3317, Morelia
Site US702, Morton Grove
Site US3226, Vernon Hills
Site CZ3225, Uherské Hradiště
Site US3300, Oklahoma City
Site US3319, Austin
Site US3331, Colorado Springs
Site US3227, Palm Desert
Site US3332, Santa Maria
Site US219, Palo Alto
Site US828, La Jolla
Site CO3326, Barranquilla, Atlantico
Site CO3297, Bogotá
Site CO2826, Bucamaranga
Site CO3450, Bucaramanga
Site CO3451, Santiago de Cali
Site CZ3388, Prague
Site CZ3376, Praha-Nusle
Site CZ3449, Zlín
Site HU3447, Debrecen
Site PL3233, Bialystok
Site PL3391, Bialystok
Site PL2893, Bydgoszcz
Site PL3603, Krakow
Site PL3601, Lublin
Site PL3600, Warsaw
Site PL3599, Warsaw
Collaborators (1)
Janssen Biotech, Inc.
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY